Mar 6 2008, 8:00 AM EST
News source: Business Wire
CBI Services, a business unit within the Commonwealth Biotechnologies, Inc. group of companies (NASDAQ Capital Market:CBTE), has been notified that its patent "Detection and Quantification of Human Herpes Viruses" was issued by the United States Patent and Trademark Office on March 4, 2008 as US Patent 7,338,761. Robert B. Harris, President, CBI, and Thomas R. Reynolds, Executive Vice President, CBI, are co-inventors of the patent which has been assigned to Vigen Laboratories, Wilmette, IL. The development work leading to the patent was done at CBI under contract to Vigen Laboratories. Under an exclusive royalty-bearing license agreement with Vigen Laboratories, CBI has been performing the assays detailed in the patent for the past seven years for physicians and clinics across the country. Now that it is patent protected, the technology will be offered to third party licensees. CBI and Vigen will share equally in any licensing and royalty stream from a third party licensee.
There are eight known human herpes viruses ("HHVs"). The alpha herpes viruses include the simplex viruses, HSV 1 and HSV 2, and varicellovirus, HHV 3. The beta herpes viruses include cytomegalovirus (HHV 5), HHV 6, and HHV 7 (Roseolovirus). The gamma herpes viruses include HHV 4 (Epstein Barr virus) and HHV 8 (Rhadinovirus).
It is estimated that more than 90% of the world's population is infected with EBV, which is associated with infectious mononucleosis (glandular fever). There is also a well-established relationship between Epstein Barr virus and oncogenesis, particularly in relation to Burkitt's lymphoma nasopharyngeocarcinoma. Infection also is associated with immuno-suppressed patients and with patients suffering from Hodgkin's disease. Cytomegalovirus is also significant in today's population and is known to cause lung infections in immune-suppressed persons. Infection with HHV 5 is believed to be transmitted by saliva, sexual contact, and through blood transfusions. Epstein Barr and cytomegalovirus are both associated with chronic-fatigue syndrome (CFS). HHV 1 and 2 are well-known causative agents of genital herpes. Less clearly characterized is the pathogenic role of HHV 6, associated with roseola and infantum infection in children and with immuno-compromised patients. The influence of HHV 6 infection in AIDS patients may be important but is unclear. Perhaps the most significant aspect to HHV 6 infection is its association with multiple sclerosis and chronic fatigue syndrome. However, no definitive viral connection has yet been made. At present there is no clear evidence for the direct involvement of HHV 7 in any human disease, but it has been suggested that it is associated in HHV 6 related infections. HHV 8 appears to be linked with Karposi's Sarcoma.
CBI's assay platform provides rapid and specific assay of each of the various HHVs down to as few as 10 copies of viral DNA in patient samples. The assay has been successfully applied to peripheral blood serum, sputum, cerebrospinal fluid, and various laboratory preparations. The CBI assay platform for the different HHVs offers a significant advance for detecting, identifying, and monitoring the course of infection.
"This assay platform was developed at CBI to meet the research needs of our customer, Vigen Laboratories," said Dr. Robert B. Harris, co-inventor and President of CBI. "We rapidly moved the assay platform from the lab bench and offered this service to clinicians who use the assay to help assess on-going treatment of their patients. With our intellectual property now protected, we will look to out-license this technology to a clinical laboratory service provider who can commercialize the assay on a large scale."
"Having this assay adds to CBI's pre-clinical and clinical expertise in the infectious disease arena and should help demonstrate the linkage between these viruses and critical diseases," explained Bill Philip, Presiden
ADVERTISEMENT
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||
ADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All